JACOBSON PHARMA (02633): Appointing contractor to advance the construction of Tai Po Innovation Park infrastructure project.
Jacobson Pharmaceuticals (02633) announced that on April 1, 2026, the consultant (Square Jim Architectural and Engineering Design Consultants Limited) representing the company's indirectly wholly-owned subsidiary, Sum Pharmaceutical, signed an acceptance letter to confirm the acceptance of the tender submitted by the contractor (Ryan Construction Limited) for specific infrastructure development and special facilities engineering at the Tai Po plant for a total contract amount of HK$607.2 million.
JACOBSON PHARMA (02633) announced that on April 1, 2026, on behalf of the company's indirectly wholly-owned subsidiary, Summit Pharmaceuticals Limited, they signed an acceptance letter to confirm the appointment of the contractor (Ryan Construction Limited) for the specific infrastructure development and specialized facility engineering works submitted for tender at the Tai Po factory, with a total contract value of HK$607.2 million.
In 2025, Summit Pharmaceuticals acquired a dedicated pharmaceutical facility at 7 Tai Yick Street, Tai Po Industrial Estate, Tai Po, New Territories, Hong Kong. Summit Pharmaceuticals plans to establish ten new intelligent pharmaceutical production lines at this facility, covering sterile eye drops, solid dosage forms, and oral liquid medicines.
The consultant, through a public tender process, assisted Summit Pharmaceuticals in evaluating the submitted bids and provided recommendations on the specific infrastructure development and specialized facility engineering works to be provided by the contractor.
The group continues to focus on its strategic priorities in the specialty drugs and smart manufacturing sectors. With the support of the Hong Kong government's New Industrial Acceleration Plan, the Tai Po facility will become the cornerstone of this strategy. The facility will feature AI and robot-driven sterile, solid, and oral liquid dosage form production lines, aiming to support efficient and high-quality production to meet local and global healthcare needs.
The transaction is expected to bring significant benefits to the group. From a strategic perspective, this move consolidates the company's leading position in the pharmaceutical industry and aligns with Hong Kong's vision to become an advanced industrial hub. In terms of innovation, the facility will use advanced technology and collaborative capabilities to enhance production efficiency, quality, and competitiveness, supporting the group's long-term growth objectives.
Related Articles
Southchip Semiconductor Technology (Shanghai) (688484.SH) has obtained approval from the Shanghai Stock Exchange for the issuance of convertible bonds.
CH Treasures NM (02439) plans to offer a discount of about 20% for the sale of up to 200 million shares, raising a net amount of approximately HK$45.4 million.
Kao Sheng Group Holdings (01283): Chan Hak Kan appointed as independent non-executive director
Southchip Semiconductor Technology (Shanghai) (688484.SH) has obtained approval from the Shanghai Stock Exchange for the issuance of convertible bonds.
CH Treasures NM (02439) plans to offer a discount of about 20% for the sale of up to 200 million shares, raising a net amount of approximately HK$45.4 million.
Kao Sheng Group Holdings (01283): Chan Hak Kan appointed as independent non-executive director
